See the DrugPatentWatch profile for tigecycline

Tigecycline is a broad-spectrum antibiotic, primarily used to treat various types of bacterial infections. According to the drug's prescribing information, tigecycline has activity against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria [1].

More specifically, tigecycline is active against bacteria such as Staphylococcus aureus (methicillin-susceptible and -resistant), Streptococcus agalactiae, Streptococcus pneumoniae, Streptococcus pyogenes, Enterococcus faecalis, Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, and others [1]. It is important to note that tigecycline is not indicated for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections outside of the hospital setting [2].

Tigecycline is a glycylcycline antibiotic, a class of drugs that is a derivative of tetracyclines [3]. It works by inhibiting bacterial protein synthesis, which ultimately leads to bacterial death [1].

In summary, tigecycline is a broad-spectrum antibiotic that is primarily used to treat various types of bacterial infections, including those caused by Gram-positive, Gram-negative, and anaerobic bacteria.

Sources:
[1] Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc. "TIGECYCLINE (tigecycline) for injection, for intravenous use. Full Prescribing Information." April 2010. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021867s013lbl.pdf>.
[2] "Tigecycline (systemic)." Micromedex Solutions. DrugPatentWatch.com. <https://www.drugpatentwatch.com/drugs/tigecycline>.
[3] "Tigecycline." National Library of Medicine. MedlinePlus. <https://medlineplus.gov/druginfo/meds/a608045.html>.